文献速递基础与转化研究临床试验与 GCP

CAR转导自然杀伤细胞治疗CD19阳性淋巴肿瘤

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
PubMed 文献 · N Engl J Med · 2020-01-01

这项1/2期试验将脐血来源的HLA错配抗CD19 CAR-NK细胞单次输注给11例复发或难治性CD19阳性癌症患者,未出现细胞因子释放综合征、神经毒性或移植物抗宿主病,8例(73%)有缓解,其中7例完全缓解。

要点

  • 抗CD19 CAR-NK细胞单次输注未引起细胞因子释放综合征、神经毒性或移植物抗宿主病。
  • 11例可评估患者中8例(73%)缓解,7例完全缓解,缓解在输注后30天内出现。
  • 未达到最大耐受剂量,输注的CAR-NK细胞低水平扩增并持续至少12个月。

核心结论

  • 在11例复发或难治性CD19阳性癌症患者中,多数对CAR-NK细胞治疗有缓解且未出现主要毒性作用。

研究设计与样本

  • 1/2期试验,将脐血来源的HLA错配抗CD19 CAR-NK细胞给予11例复发或难治性CD19阳性非霍奇金淋巴瘤或慢性淋巴细胞白血病患者。
  • NK细胞经逆转录病毒载体转导表达抗CD19 CAR、白细胞介素-15和诱导型半胱天冬酶9安全开关,体外扩增后单次输注。
  • 输注前接受淋巴细胞清除化疗,CAR-NK细胞剂量为1×10^5、1×10^6或1×10^7个细胞/千克体重。

主要发现

  • 未发生细胞因子释放综合征、神经毒性或移植物抗宿主病,包括白细胞介素-6在内的炎性细胞因子水平较基线未升高。
  • 未达到最大耐受剂量。
  • 11例治疗患者中8例(73%)有缓解,其中7例(4例淋巴瘤和3例CLL)完全缓解,1例Richter转化成分缓解但CLL持续。
  • 缓解迅速,在所有剂量水平输注后30天内出现。
  • 输注的CAR-NK细胞扩增并低水平持续至少12个月。

临床怎么用

  • 对于复发或难治性CD19阳性淋巴肿瘤,抗CD19 CAR-NK细胞可作为潜在治疗选择,且未观察到细胞因子释放综合征、神经毒性或移植物抗宿主病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: In this phase 1 and 2 trial, we administered HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood to 11 patients with relapsed or refractory CD19-positive cancers (non-Hodgkin's lymphoma or chronic lymphocytic leukemia [CLL]). NK cells were transduced with a retroviral vector expressing genes that encode anti-CD19 CAR, interleukin-15, and inducible caspase 9 as a safety switch. The cells were expanded ex vivo and administered in a single infusion at one of three doses (1×105, 1×106, or 1×107 CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy. RESULTS: The administration of CAR-NK cells was not associated with the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. The maximum tolerated dose was not reached. Of the 11 patients who were treated, 8 (73%) had a response; of these patients, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transformation component but had persistent CLL. Responses were rapid and seen within 30 days after infusion at all dose levels. The infused CAR-NK cells expanded and persisted at low levels for at least 12 months. CONCLUSIONS: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020. PMID: 32023374. doi:10.1056/NEJMoa1910607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。